aifollow.news
返回 TechCrunch AI 报道
TechCrunch AI 报道· · 原发布时间 AI 评分46

Isomorphic Labs 融资 50 亿美元,推进药物候选项目进入临床试验

AI 辅助摘要

AI 药物研发公司 Isomorphic Labs 完成 50 亿美元 C 轮融资,计划推动其药物候选项目进入临床试验,并继续开发药物设计引擎、拓展药物类型。公司称,其肿瘤学和免疫学项目已取得积极的临床前结果;临床前结果尚不能说明人体试验成效。

正文 · 原文

该语言的正文暂不可用,当前显示已有版本。

Isomorphic Labs , the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.

The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.

Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model , said its program has yielded “positive preclinical results” in oncology and immunology. The lab has struck deals with pharma giants like Eli Lilly, Novartis, and Johnson & Johnson.

The new funding, which comes on the heels of a $2.1 billion Series B round in May, will be used to continue developing its drug-design engine, as well as to foray into more types of medicine.

The Series C is Isomorphic’s first fundraise since its founder and CEO, Demis Hassabis, left his position as head of DeepMind to focus on drug discovery, which also saw him moving into a chairman role at DeepMind. Hassabis and then-director of DeepMind John Jumper won the Nobel Prize in chemistry for the lab’s work on AlphaFold, a system that predicts the 3D structure of proteins with nothing more than their genetic sequence.

Isomorphic did not disclose its new valuation. Bloomberg reported earlier this month that the lab was looking to raise funding at a $50 billion valuation.

发现内容有误?提交纠错